First semaglutide generics launched in India India is the first market where semaglutide generics are entering at scale, providing a benchmark for how competition, pricing, and supply chains evolve once multiple players launch simultaneously
The figure forms a significant part of the $6.8 billion the Danish company said it plans to spend on production this year as it races to ramp up output of its incredibly popular GLP-1 drug semaglutide, sold as Ozempic for diabetes and Wegovy for obesity and cardiovascular problems
Because of these unknowns, the FDA label says to think about the health benefits of breastfeeding alongside your need for Wegovy and any possible effects on your baby , whether from the medication or from your health condition
They mimic natural hormones that help the body produce insulin, control blood sugar, and reduce appetite
Clinical application of GLP-1 in atherosclerosis There is substantial evidence that GLP-1 is involved in the function of the cardiovascular system [9]